Tumor immunotherapy has become a new hotspot for cancer treatment. Various immunotherapies, such as immune checkpoint inhibitors, oncolytic viruses (OVs), cytokines, and cancer vaccines, have been used to treat tumors. They operate through different mechanisms, along with certain toxicities and side effects. Understanding the mechanisms by which immunotherapy modulates the immune system is essential for improving the efficacy and managing these adverse effects. This article discusses various currently approved cancer immunotherapy mechanisms and related agents approved by the Food and Drug Administration, the European Medicines Agency, and the Medicines and Medical Devices Agency. We also review the latest progress in immune drugs approved by the National Medical Products Administration, including monoclonal antibodies, cytokines, OVs, and chimeric antigen receptor-T cell therapy, to help understand the clinical application of tumor immunotherapy.

2024-01-01·Bioactive Materials

From oncolytic peptides to oncolytic polymers: A new paradigm for oncotherapy

Review

作者: Yin, Dengke ; Xiao, Chunsheng ; Liu, Wanguo ; Liu, Hanmeng ; Shen, Wei ; Yang, Zexin

Traditional cancer therapy methods, especially those directed against specific intracellular targets or signaling pathways, are not powerful enough to overcome tumor heterogeneity and therapeutic resistance. Oncolytic peptides that can induce membrane lysis-mediated cancer cell death and subsequent anticancer immune responses, has provided a new paradigm for cancer therapy. However, the clinical application of oncolytic peptides is always limited by some factors such as unsatisfactory bio-distribution, poor stability, and off-target toxicity. To overcome these limitations, oncolytic polymers stand out as prospective therapeutic materials owing to their high stability, chemical versatility, and scalable production capacity, which has the potential to drive a revolution in cancer treatment. This review provides an overview of the mechanism and structure-activity relationship of oncolytic peptides. Then the oncolytic peptides-mediated combination therapy and the nano-delivery strategies for oncolytic peptides are summarized. Emphatically, the current research progress of oncolytic polymers has been highlighted. Lastly, the challenges and prospects in the development of oncolytic polymers are discussed.

2023-08-30·Annals of translational medicine

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?

Communications

作者: Wongariyapak, Amarin ; Roulstone, Victoria ; Melcher, Alan A ; Harrington, Kevin J ; Pedersen, Malin

100 项与 Oncolytic viruses(EpicentRx, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床1期	-	EpicentRx, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASGCT2011	N/A	三阴性乳腺癌	-	Oncolytic Viruses (NV1066)	膚顧顧積餘鏇糧顧糧醖(鏇膚艱醖築繭構衊鹽齋) = 繭廠鬱構築製廠範襯構製繭觸壓淵鹽夢願膚鏇 (糧淵廠膚壓觸築範膚鹽 ) 更多	-	2011-05-01
				Oncolytic Viruses (Control (No treatment))	淵鏇範襯壓範壓鹹壓鑰(憲鏇憲遞繭窪夢範遞衊) = 製廠餘遞鏇鑰廠廠鑰壓鑰積製襯鬱範憲蓋餘願 (鑰願遞餘淵醖艱襯膚鑰 )
ASGCT2009	N/A	镰状细胞遗传性状	-	Oncolytic Viruses (Sickle red blood cells (RBC))	(蓋淵糧鑰製膚顧糧鬱餘) = 憲範憲網鑰膚膚鹽積壓餘鑰鑰鏇憲膚願觸齋遞 (餘餘壓餘遞願願餘鏇構 )	-	2009-05-01
				Oncolytic viruses	(蓋淵糧鑰製膚顧糧鬱餘) = 簾網襯簾觸願鏇鑰衊襯餘鑰鑰鏇憲膚願觸齋遞 (餘餘壓餘遞願願餘鏇構 )
ASGCT2004	N/A	毒性	-	Oncolytic Viruses (Wildtype adenovirus)	餘壓獵鑰範構範淵夢襯(選壓衊選獵簾觸簾艱壓) = 鑰憲簾鹽憲選膚繭鹽遞鏇選衊構壓鬱醖廠顧獵 (網鹹遞醖襯選鬱網鹹鹽 )	积极	2004-05-01